Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from sitagliptin to liraglutide in type 2 diabetes inadequately controlled on sitagliptin and metformin
2012-004931-22Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to 26 weeks. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004931-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004931-22.